Abstract: A positive electrode active material precursor includes Ni and Mn and secondary particles formed by the aggregation of a plurality of primary particles. The secondary particles have a ratio of a core area to a total area of the particles ranging from 28.7% to 34.1%, and a porosity ranging from 11.3% to 11.7%. Also provided is a method for preparing the positive electrode active material precursor. Additionally, a positive electrode active material including a reaction product of the positive electrode active material precursor and a lithium raw material is provided. Also provided is a method for preparing a positive electrode active material using the positive electrode active material precursor.

Abstract: There is provided a smoking material wrapper having micropores, wherein when the smoking material wrapper is divided into three regions at equal intervals from an upstream distal end based on the case where the smoking material wrapper is applied to a smoking article, an average porosity is greater as a region becomes closer to a downstream. According to an embodiment of the present disclosure, the micropores have a pore size of 10 ?m to 50 ?m, and are formed by a perforation method using plasma. The wrapper may maintain functionality as a wrapping material due to low visibility or the like, and may minimize a dilution ratio decreased due to burning of a smoking material unit while maintaining a basic dilution ratio when the smoking material wrapper is applied to a smoking article.

Abstract: The present invention relates to a method for preparing a lyophilized cyclophosphamide composition, wherein 99% or more of the finally prepared lyophilized cyclophosphamide composition is reconstituted within 15 seconds when water for pharmaceutical use is injected thereinto at a ratio of 50 mL per 1 g of anhydrous cyclophosphamide, comprising a step of dissolving D-mannitol or lactose, as a lyoprotectant, and cyclophosphamide in a water solvent in a selected reaction vessel; and a lyophilized cyclophosphamide composition for injection prepared thereof.

Abstract: The present invention relates to a method for preparing a lyophilized cyclophosphamide composition, wherein 99% or more of the finally prepared lyophilized cyclophosphamide composition is reconstituted within 15 seconds when water for pharmaceutical use is injected thereinto at a ratio of 50 mL per 1 g of anhydrous cyclophosphamide, comprising a step of dissolving D-mannitol or lactose, as a lyoprotectant, and cyclophosphamide in a water solvent in a selected reaction vessel; and a lyophilized cyclophosphamide composition for injection prepared thereof.

Abstract: The present invention relates to a method for preparing a lyophilized composition with improved stability and solubility, which comprises dissolving cyclophosphamide, sodium chloride, and D-mannitol in water as a solvent in a reaction container at 40° C. to 70° C., and a lyophilized cyclophosphamide composition for injection prepared according to the method.

Abstract: The present invention relates to a solid preparation including a Pelargonium sidoides extract and a silicic acid compound, which is allowed to be formulated in a solid form by direct adsorption of the Pelargonium sidoides extract onto a silicic acid compound, and a preparation method thereof. Since the solid preparation including the Pelargonium sidoides extract and the silicic acid compound of the present invention has higher stability than a liquid preparation such as syrup, and has no additives such as sugars, there is no concern about microbial contamination or spoilage of the preparation. In addition, it is possible to pack the solid preparation individually. Since the solid preparation is smaller in volume than the liquid preparation, it is highly portable, and there is also a convenience that no additional tools are needed to take the drug. Further, the active ingredient can be taken at the equal amount every time.

Abstract: Disclosed are biocompatible polymeric nanoparticles for drug delivery and a method for preparing the same. They can be prepared by mixing a tri-block copolymer, PEG, and a drug at a predetermined temperature to give a homogeneous polymeric mixture; solidifying the homogeneous polymeric mixture at room temperature; and dissolving the solidified polymeric mixture in an aqueous solution. Based on a polymer melting process, the method makes it easy to produce poloxamer nanoparticles at low cost. The nanoparticles show desired particle sizes suitable for use in drug delivery and a uniform particle size distribution. Consisting of a bilayer structure, the nanoparticles can contain sparingly soluble drugs. Also, the nanoparticles contain no organic solvents and are thus safe to the body because they are free of organic solvent residuals.

Abstract: A microemulsion composition comprising biphenyldimethyldicarboxylate (DDB), a co-surfactant, a surfactant and an oil provides an improved stability and a high in vivo bioavailability of biphenyldimethyldicarboxylate when orally administered.